ELTX

ELTX

USD

Elicio Therapeutics Inc. Common Stock

$5.500+0.260 (4.962%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$5.240

Haut

$5.750

Bas

$5.130

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

87.7M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.04M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $3.342Actuel $5.500Haut $11.45

Rapport d'Analyse IA

Dernière mise à jour: 1 mai 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

ELTX (Elicio Therapeutics Inc. Common Stock): What's Happening with the Stock and What to Watch For

Stock Symbol: ELTX Generate Date: 2025-05-01 06:12:05

Let's break down what's been going on with Elicio Therapeutics stock based on the latest information. We'll look at the news, how the price has been moving, and what some predictions suggest.

Recent News Buzz

Okay, so what's the general feeling from the recent news about Elicio? It seems pretty positive overall.

First off, the company brought in a new Chief Strategy and Financial Officer, plus some other new folks. That kind of news usually suggests the company is building out its team and operations, which can be a good sign for stability and future plans.

Then, a firm called HC Wainwright & Co. came out and said they still like the stock, keeping their "Buy" rating and a $10 price target. Getting a thumbs-up from analysts, especially with a price target well above where the stock is trading now, is definitely seen as a positive signal in the market.

Finally, Elicio shared their 2024 financial results and gave updates on their work. The big news here is they finished signing up patients for a key Phase 2 study (AMPLIFY-7P). They also mentioned they're on the same page with the FDA about important parts of their plan. Finishing enrollment and getting FDA alignment are significant steps forward for a biotech company, suggesting their clinical trials are progressing.

So, putting it together, the news flow points towards operational strengthening, positive analyst sentiment, and good progress on the clinical trial front.

Price Check

Now, let's look at what the stock price itself has been doing. If you look at the last few months, it's been a bit of a rough ride. The price was trading up around $9 or more back in February, but it's seen a pretty significant drop since then. There was a particularly sharp fall around the end of March and early April.

Lately, though, in the latter half of April, the price seems to have settled into a range, mostly trading between roughly $4.70 and $5.30. The last recorded price (Previous Close) was $4.81, which is right in that recent trading zone.

What about the very near future? An AI prediction tool suggests the price might stay flat today but then potentially tick up a bit over the next couple of days, maybe gaining a few percent.

Outlook & Ideas

So, we have positive news updates and analyst support, but the stock price has taken a big hit recently, although it seems to be stabilizing. The AI predicts a small upward move soon.

This situation is a bit mixed because of that large prior price drop. However, the recent positive news and the AI's short-term forecast lean towards a potential stabilization or even a slight bounce from current levels. It doesn't scream "sell," and the positive developments could attract attention.

If someone were considering this stock, where might they look? Given the recent trading range and the AI's prediction of a slight rise, the current price area around $4.81, or perhaps slightly higher up to the $5.09 mark (as suggested by some recommendation data), could be seen as potential entry points if you believe the positive news and AI prediction will lead to a bounce.

What about managing risk? If the price doesn't move up and instead continues to fall, a stop-loss order around $4.33 (again, referencing recommendation data) could be a way to limit potential losses. That level is below the recent lows we've seen. On the upside, if the stock does climb, a potential take-profit target might be around $5.18, which aligns with the recent trading range high and the AI's predicted short-term move. These are just ideas for managing potential outcomes.

Company Context

It's important to remember that Elicio Therapeutics is a clinical-stage biotechnology company. This means their main focus is developing new medicines, particularly for cancer treatments. Because of this, news about their clinical trials, results, and interactions with regulatory bodies like the FDA are incredibly important and can cause big swings in the stock price.

Also, keep in mind it's a smaller company with a market value under $80 million and relatively low daily trading volume. This means that even a moderate amount of buying or selling activity can have a noticeable impact on the share price, potentially leading to more volatility compared to larger, more heavily traded stocks.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Investing in stocks involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Actualités Connexes

GlobeNewswire

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the

Voir plus
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics with a Buy and maintains $10 price target.

Voir plus
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target
GlobeNewswire

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA") on key elements of

Voir plus
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 5 mai 2025, 12:35

BaissierNeutreHaussier

65.2% Confiance

Risque et Trading

Niveau de Risque4/5
Risque Élevé
Adapté Pour
Valeur
Guide de Trading

Point d'Entrée

$5.50

Prise de Bénéfices

$5.88

Stop Loss

$4.87

Facteurs Clés

La valeur K 18.8 est inférieure à la valeur D 22.5 et inférieure à 20, suggérant des conditions de survente
Le DMI montre une tendance baissière (ADX:25.1, +DI:32.6, -DI:33.7), suggérant la prudence
Le cours actuel est extrêmement proche du niveau de support ($5.46), suggérant une forte opportunité d'achat
Le MACD 0.0968 est en dessous de la ligne de signal 0.1287, indiquant un croisement baissier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.